Real-world treatment-transition pathways and dosing patterns of insulin degludec/liraglutide in Chinese adults with type 2 diabetes

Background and aims: To describe real-world treatment-transition pathways, early IDegLira dosing patterns, treatment simplification, and observed short-term clinical outcomes among Chinese adults with type 2 diabetes (T2D).

Methods

This multicenter, non-interventional, retrospective observational registry included 1499 adults with T2D who initiated IDegLira in routine practice across 13 provinces and regions in China from April 2022 to December 2023. The five mutually exclusive prior-treatment pathways were non-injectable therapy, basal insulin, multiple daily injections (MDI), insulin plus GLP-1RA, and GLP-1RA-based therapy. Treatment decisions were physician-directed. Eligible patients had documented continuous use of once-daily IDegLira (the fixed-ratio combination [FRC]) for at least 3 months. Early dosing was defined as the starting dose, dose titration, and dose documented at approximately 12 weeks. Exploratory linear models estimated crude and covariate-adjusted between-pathway differences in paired HbA1c and body-weight change.